We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Unilever Plc | LSE:ULVR | London | Ordinary Share | GB00B10RZP78 | ORD 3 1/9P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
17.00 | 0.43% | 3,979.00 | 3,978.50 | 3,979.00 | 3,982.50 | 3,956.00 | 3,974.50 | 744,151 | 16:18:41 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Perfume,cosmetic,toilet Prep | 59.6B | 6.49B | 2.5958 | 15.34 | 99.5B |
Date | Subject | Author | Discuss |
---|---|---|---|
11/12/2023 11:07 | Bernstein raises Unilever to 'market-perform' (underperform) - price target 3,600 (3,800) pence Jefferies cuts Unilever to 'underperform' (buy) - price target 3,300 (5,000) pence | philanderer | |
11/12/2023 10:57 | CT’s Smith tops up Unilever position Columbia Threadneedle manager Jeremy Smith has increased his position in consumer giant Unilever (ULVR) as he believes a turnaround is coming after a tough decade. He topped up his holding in the Citywire Elite Companies AA-rated stock in his £133m CT UK Equity Alpha Income fund to take advantage of ‘volatility in the shares after the firm’s quarterly earnings statement’. He said he was ‘encouraged by changes at the executive and board levels’, where a new chairman, chief executive, and chief financial officer have ‘improved the quality of the management team’. ‘Unilever has had a poor decade due to a lack of focus and using too many conflicting key performance indicators,’ said Smith. ‘However, we believe it now has significant levers to accelerate organic growth and improve returns.’ Smith said the group is ‘well prepared for increasingly stringent regulation around plastic waste’ and is working toward products that appeal to ‘environmental citywire.com | philanderer | |
11/12/2023 08:23 | Long timers at Unilever will know that there has always been gossip about breaking the company up. More pertinently, the erosion of talent and relentless outsourcing of marketing and technical innovation is, imo, the biggest barrier to growth. The products are good, if a tad overpriced. | sparkling banana | |
11/12/2023 00:54 | Unilever faces break-up battle after ‘virtue signalling’ retreat | philanderer | |
30/11/2023 09:50 | Another year's low. | action | |
30/11/2023 05:27 | I look to have picked the wrong time to try and emulate Nick Train Away from my financials (dubious if I m being charitable) both this Ulvr and Dge have been initial disappointments but still early days. It would be better if ulvr had pulled out of Russia as does raise a question mark to my mind and this latest furore over food price rises will again do nothing in the short term for the share price. But as they say I m in it for the long haul arduous though it may seem. Hope I ve timed it right | jubberjim | |
30/11/2023 00:36 | Chart support around 3500p | philanderer | |
29/11/2023 21:29 | Also reached new low of the year. | action | |
29/11/2023 10:06 | JPMorgan cuts Unilever price target to 3,600 (3,900) pence - 'underweight' | philanderer | |
28/11/2023 14:18 | ULVR share price is nowhere near strong enough ad there would need to be an equity element with new shares issued. Since the last reported interest the cost of detveting debt has soared, so it's a complete non starter - at least at this point. | essentialinvestor | |
28/11/2023 13:50 | I don't think fund managers want it, that's why they pulled the last offer after about 5 days, everyone said it was crazy and been proved right, just my opinion. | montyhedge | |
25/11/2023 11:02 | 12.05.2023 - GSK said Friday that it has now sold 240 million shares in consumer healthcare business HLN for 335 pence each, raising GBP804M (USD1.01BN). Following the sale GSK will continue to hold 955M HLN shares (10.3%) I have often thought ULVR might come back in with another offer for HLN, Pfizer were looking to offload their position back in May, but no TR1 to date, new CEO new strategy, so we will see where he takes us.. | laurence llewelyn binliner | |
25/11/2023 10:54 | I don't think Pfizer has sold a single share post IPO. GSK has reduced its position. | pdosullivan | |
25/11/2023 10:53 | That 50bn was the enterprise value for Haleon. You have to add net debt to the market cap when considering a deal. HLN would cost an acquirer a lot more than 30bn today. | pdosullivan | |
24/11/2023 15:41 | Pfizer owned 32% of HLN back in May and were reducing their position, who bought them..?, their stake was worth around USD10BN back then.. | laurence llewelyn binliner | |
24/11/2023 11:53 | montyhedge if they turned down 50 billions back then, what makes you think they will accept an offer 40% lower today? | alotto | |
24/11/2023 11:16 | >>now they could get for roughly 30 billion>> Plus debt, so roughly £40 billion. | zho | |
24/11/2023 11:03 | I don't know why they don't bid for Haleon they offered 50 billion for a few days before they pulled the offer, now they could get for roughly 30 billion. | montyhedge | |
23/11/2023 13:37 | Unilever is slowly divesting food/grocery, which appears to be overlooked in some of the comments here. Spreads went a few years ago, most of their tea business more recently. They may largely be out of this segment longer term. | essentialinvestor | |
22/11/2023 21:00 | Totally agree Anhar. We use a large number of Unilever products. CIF as an example. I tried a cheaper alternative. Absolutely rubbish and it worked out more expensive as one had to use so much more. If I told my wife no more Dove soap, it would world war 3. Yes ok can down grade bleach, but that’s about it . | mastey | |
22/11/2023 12:35 | Load of boll imo from Breakingwind. I'm certainly not dumping my ULVR on the strength of some scribbler. | anhar |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions